HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sisson, J. C. Search for Related Content PubMed PubMed Citation Articles by Sisson, J. C.

What Promise the Preliminary Tests of Coronary Artery Disease?

University of Michigan Medical Center, Ann Arbor, Michigan

Correspondence: For reprints contact: James C. Sisson, MD, Nuclear Medicine Division, Univ. of Michigan Medical Center, Ann Arbor, MI 48109.

ABSTRACT

For some patients with coronary artery disease (CAD), bypass operations prolong life. Angiograms, incurring some risk and considerable expense, are pre-requisites to surgical therapy; they delineate the region and extent of disease. However, many people who complain of chest pain do not have disease that can be benefited by operation. Therefore, tests that will safely and economically select the appropriate individuals for angiography are most welcome. Yet, if the preliminary tests falsely declare affected people to be free of CAD, they will deny these patients angiography, and, consequently, surgical treatment that would prolong their lives. Decision analysis determines that a false-negative rate of less than 2% is necessary for tests preliminary to angiography if the average survival of patients is not to be shortened. No currently used procedure has attained this sensitivity. Radionuclide ventriculography approaches this precision, but its sensitivity must be sustained in more broadly based studies.